TLDR Johnson & Johnson reports Q4 fiscal 2025 earnings before market open on January 21 with EPS expected at $2.49-$2.50 Stock has surged 47-48.7% in the past yearTLDR Johnson & Johnson reports Q4 fiscal 2025 earnings before market open on January 21 with EPS expected at $2.49-$2.50 Stock has surged 47-48.7% in the past year

Johnson & Johnson (JNJ) Stock: What to Expect From Earnings Wednesday

2026/01/20 21:20
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • Johnson & Johnson reports Q4 fiscal 2025 earnings before market open on January 21 with EPS expected at $2.49-$2.50
  • Stock has surged 47-48.7% in the past year, crushing the S&P 500’s 14.7% return over the same period
  • Stelara faces mounting pressure from multiple biosimilar competitors launched in 2025, expected to weigh heavily on Q4 results
  • Company announced $55 billion U.S. investment plan including a $2 billion North Carolina biologics facility creating 5,000 jobs
  • Maryland jury awarded $1.56 billion in talc lawsuit, the largest single-plaintiff verdict against JNJ, which plans to appeal

Johnson & Johnson releases fourth-quarter fiscal 2025 results on Wednesday, January 21, before the market opens. Analysts project earnings per share will climb 22% to around $2.49-$2.50, while revenue should grow 7.3% year-over-year to approximately $24.14 billion.


JNJ Stock Card
Johnson & Johnson, JNJ

The stock has been on fire. JNJ shares rocketed 47-48.7% over the past 12 months, obliterating the S&P 500’s 14.7% advance.

Wall Street analysts show mixed feelings heading into the report. Seven rate the stock a Buy while five recommend Hold, according to TipRanks. The average price target of $221.09 implies only 1.1% upside from current levels.

The Dividend King maintains its impressive payout streak. JNJ has increased dividends for over 60 consecutive years and currently pays $1.30 per share quarterly, yielding 2.50%.

Key Drugs Drive Innovative Medicine Growth

The Innovative Medicine segment should power Q4 results. Darzalex, Tremfya, and Erleada are expected to post strong numbers. Analysts forecast Darzalex sales at $3.74 billion, Tremfya at $1.36 billion, and Erleada at $936 million.

Newer launches are picking up steam. Carvykti, Tecvayli, Talvey, Rybrevant, Caplyta, Lazcluze, and Spravato should all contribute to growth.

But Stelara is getting crushed. Multiple biosimilar versions hit the U.S. market in 2025 from Amgen, Teva, Samsung Bioepis/Sandoz, and others. The loss of exclusivity hammered the Innovative Medicines segment by 1,070 basis points in Q3. Analysts expect the damage to accelerate in Q4 as more biosimilars enter the market. Stelara sales are pegged at just $1.36 billion.

Imbruvica faces its own challenges from oral competitors and Medicare Part D redesign impacts. Estimates stand at $670 million. Generic competition for Zytiga and Remicade continues nibbling away at sales.

The MedTech business has bounced back in recent quarters. Cardiovascular acquisitions Abiomed and Shockwave are performing well. Surgery, Vision, and electrophysiology products are gaining traction. Consensus estimates peg MedTech revenue at $8.71 billion.

China remains problematic. The government’s volume-based procurement program keeps squeezing MedTech margins through forced price cuts.

Recent Pipeline and Legal Developments

JNJ dropped positive Caplyta data on January 16. Phase 3 trials showed the drug boosted remission rates in major depressive disorder when combined with antidepressants. After six months, 65% of patients achieved remission. The FDA approved Caplyta for this use in November 2025.

The company cut a deal with the Trump administration on drug pricing while securing tariff exemptions. It’s also moving forward with major U.S. manufacturing expansion plans totaling $55 billion. A $2 billion biologics plant in Wilson, North Carolina will create roughly 5,000 jobs.

The talc litigation headache persists. A Maryland jury hit JNJ with a $1.56 billion verdict, the biggest single-plaintiff award yet, over alleged mesothelioma from baby powder. The company insists the product never contained asbestos and will appeal the decision.

2026 Guidance in Focus

Management previously signaled consensus estimates for 2026 were too conservative. Back in October, JNJ expected revenue growth above 5% versus analyst forecasts of 4.6%. Earnings per share were projected roughly 5 cents higher than the October consensus of $11.39.

The stock trades at 19.01 times forward earnings, above the industry average of 17.73 and JNJ’s five-year mean of 15.65. The company has topped earnings expectations in each of the last four quarters with an average beat of 3.75%.

Investors will scrutinize updated 2026 guidance and management commentary on biosimilar competition, talc litigation, and pipeline progress when JNJ reports January 21.

The post Johnson & Johnson (JNJ) Stock: What to Expect From Earnings Wednesday appeared first on Blockonomi.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Coinbase CLO: Clarity Act Deal on Stablecoin Yield ‘Very Close’

Coinbase CLO: Clarity Act Deal on Stablecoin Yield ‘Very Close’

The post Coinbase CLO: Clarity Act Deal on Stablecoin Yield ‘Very Close’ appeared on BitcoinEthereumNews.com. In brief Coinbase Chief Legal Officer Paul Grewal
Share
BitcoinEthereumNews2026/04/02 19:54
South Korea Stablecoin Legislation: FSC Accelerates Crucial Regulatory Framework and Tax Review

South Korea Stablecoin Legislation: FSC Accelerates Crucial Regulatory Framework and Tax Review

BitcoinWorld South Korea Stablecoin Legislation: FSC Accelerates Crucial Regulatory Framework and Tax Review SEOUL, South Korea – March 2025 – South Korea’s Financial
Share
bitcoinworld2026/04/02 18:20
How to earn from cloud mining: IeByte’s upgraded auto-cloud mining platform unlocks genuine passive earnings

How to earn from cloud mining: IeByte’s upgraded auto-cloud mining platform unlocks genuine passive earnings

The post How to earn from cloud mining: IeByte’s upgraded auto-cloud mining platform unlocks genuine passive earnings appeared on BitcoinEthereumNews.com. contributor Posted: September 17, 2025 As digital assets continue to reshape global finance, cloud mining has become one of the most effective ways for investors to generate stable passive income. Addressing the growing demand for simplicity, security, and profitability, IeByte has officially upgraded its fully automated cloud mining platform, empowering both beginners and experienced investors to earn Bitcoin, Dogecoin, and other mainstream cryptocurrencies without the need for hardware or technical expertise. Why cloud mining in 2025? Traditional crypto mining requires expensive hardware, high electricity costs, and constant maintenance. In 2025, with blockchain networks becoming more competitive, these barriers have grown even higher. Cloud mining solves this by allowing users to lease professional mining power remotely, eliminating the upfront costs and complexity. IeByte stands at the forefront of this transformation, offering investors a transparent and seamless path to daily earnings. IeByte’s upgraded auto-cloud mining platform With its latest upgrade, IeByte introduces: Full Automation: Mining contracts can be activated in just one click, with all processes handled by IeByte’s servers. Enhanced Security: Bank-grade encryption, cold wallets, and real-time monitoring protect every transaction. Scalable Options: From starter packages to high-level investment contracts, investors can choose the plan that matches their goals. Global Reach: Already trusted by users in over 100 countries. Mining contracts for 2025 IeByte offers a wide range of contracts tailored for every investor level. From entry-level plans with daily returns to premium high-yield packages, the platform ensures maximum accessibility. Contract Type Duration Price Daily Reward Total Earnings (Principal + Profit) Starter Contract 1 Day $200 $6 $200 + $6 + $10 bonus Bronze Basic Contract 2 Days $500 $13.5 $500 + $27 Bronze Basic Contract 3 Days $1,200 $36 $1,200 + $108 Silver Advanced Contract 1 Day $5,000 $175 $5,000 + $175 Silver Advanced Contract 2 Days $8,000 $320 $8,000 + $640 Silver…
Share
BitcoinEthereumNews2025/09/17 23:48

$30,000 in PRL + 15,000 USDT

$30,000 in PRL + 15,000 USDT$30,000 in PRL + 15,000 USDT

Deposit & trade PRL to boost your rewards!